

Takeda to divest select APAC assets to Celltrion for \$278M

15 June 2020 | News

Growth & Emerging Markets Business Unit increasing focus on innovative medicines for complex and rare diseases



Japanese firm Takeda Pharmaceutical Company Limited has announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter (OTC) and prescription pharmaceutical products sold exclusively in Asia Pacific to Celltrion Inc. ("Celltrion"), an Incheon, South Korea-based biopharmaceutical company specializing in the research, development and manufacturing of small molecules, biosimilars and innovative drugs. Takeda will receive \$266 million USD upfront in cash and up to an additional \$12 million USD in potential milestone payments, subject to customary legal and regulatory closing conditions.

The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products in the Cardiovascular, Diabetes and General Medicine therapeutic areas sold predominantly in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand, which are part of Takeda's Growth & Emerging Markets Business Unit.

The portfolio generated FY 2018 net sales of approximately \$140 million USD, driven by strong sales of prescription products Nesina[®] and Edarbi[®]. While the products included in the sale continue to play important roles in meeting patient needs in these countries, they are outside of Takeda's chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – that are core to its global long-term growth strategy.